Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10954785 | 0.99 | TGM2 (0.60) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3445880 | 0.96 | HTT (0.62) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3524616 | 0.91 | LMNA (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL10952216 | 0.91 | TGM2 (0.51) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL26962714 | 0.87 | L3MBTL1 (0.63) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL21070677 | 0.86 | SMN1; SMN2 (0.74) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL21069445 | 0.86 | SMN1; SMN2 (0.74) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL21069451 | 0.86 | SMN1; SMN2 (0.74) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6758924 | 0.86 | SMN1; SMN2 (0.74) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL2453444 | 0.85 | HTT (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11318132-B2 | Diversion-resistant opioid formulations | ELYSIUM THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200262864-A1 | DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-10544100-B2 | Autophagy inhibitors | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-01-28 | — | — | US | disclosed |
| US-10314839-B2 | Diversion-resistant opioid formulations | ELYSIUM THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180290980-A1 | Autophagy Inhibitors | VAN ANDEL RESEARCH INSTITUTE | 2018-10-11 | — | — | US | disclosed |
| US-20170000784-A1 | Autophagy Inhibitors | VAN ANDEL RESEARCH INSTITUTE | 2017-01-05 | — | — | US | disclosed |
| US-20160136153-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | ELYSIUM THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137607-A1 | Autophagy Inhibitors | VAN ANDEL RESEARCH INSTITUTE | 2016-05-19 | — | — | US | disclosed |
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544100-B2 | Autophagy inhibitors | BECN1, ATG7, SQSTM1 | HTT 918/4885LMNA 2419/4885SMN1; SMN2 4148/4885 |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | HTT 1885/4885LMNA 3356/4885SMN1; SMN2 3376/4885 |
| US-20160136153-A1 | DIVERSION-RESISTANT OPIOID FORMULATIONS | OPRL1, OPRK1, OPRM1 | HTT 3395/4885LMNA 4196/4885SMN1; SMN2 1206/4885 |
| US-20170000784-A1 | Autophagy Inhibitors | BRAF, HRAS, NRAS | HTT 2443/4885LMNA 1164/4885SMN1; SMN2 2066/4885 |
| US-11318132-B2 | Diversion-resistant opioid formulations | OPRL1, OPRK1, OPRM1 | HTT 3395/4885LMNA 4196/4885SMN1; SMN2 1206/4885 |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | HTT 156/4885LMNA 1560/4885SMN1; SMN2 1473/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | HTT 1885/4885LMNA 3356/4885SMN1; SMN2 3376/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | HTT 112/4885LMNA 1430/4885SMN1; SMN2 1673/4885 |
| US-20200262864-A1 | DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME | DHCR7, HSD17B13, HSD11B2 | HTT 1487/4885LMNA 1471/4885SMN1; SMN2 3636/4885 |
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | HTT 2515/4885LMNA 4204/4885SMN1; SMN2 4533/4885 |
| US-10314839-B2 | Diversion-resistant opioid formulations | OPRL1, OPRK1, OPRM1 | HTT 3395/4885LMNA 4196/4885SMN1; SMN2 1206/4885 |
| US-20160137607-A1 | Autophagy Inhibitors | BECN1, ATG7, SQSTM1 | HTT 918/4885LMNA 2419/4885SMN1; SMN2 4148/4885 |
| US-20180290980-A1 | Autophagy Inhibitors | BECN1, ATG7, SQSTM1 | HTT 918/4885LMNA 2419/4885SMN1; SMN2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.